Dabigatran etexilate: A novel oral direct thrombin inhibitor
American Journal of Health-System Pharmacy, 08/19/2011
Blommel ML et al. – Dabigatran etexilate, the first oral DTI marketed in the United States, is indicated to reduce the risk of stroke and systemic embolism in patients with non–valvular atrial fibrillation. Dabigatran may be a viable option for anticoagulation in some patients due to its oral administration, rapid onset of action, and predictable anticoagulant effects.